Speaker(s): 

Michael Duong, PharmD, Resident I, Staff Member, Geisinger - has nothing to disclose.

Erin Seddon, PharmD, Resident I, Staff Member, Geisinger - has nothing to disclose

Moderator(s): 

Sarah F. Hale, PharmD, BCPPS, Director of Pharmacy, Geisinger - has nothing to disclose. 

Learning Objectives: 

At the conclusion of this session, the participant should be able to: 

• Evaluate whether ketamine reduces 28-day in-hospital mortality compared to etomidate in critically ill adults undergoing intubation.

• Assess the incidence of cardiovascular collapse during intubation between induction agents.

• Determine whether this trial supports a change in induction agent selection in our emergency department and critical care practice.

• Summarize the typical treatment for borderline personality disorder (BPD),

• Identify the components of dialectical behavior therapy (DBT). 

• Interpret results of DBT compared to typical treatment for BPD and assess place in therapy.

Disclosure of Relevant Financial Relationships with/without Commercial Interests:

The Planning Committee consisting of Sarah F. Hale, PharmD, Brian Simpkins, PharmD, Jessica Milheim, CPhT, Clara Bishay, PharmD, and Simran Kaur, PharmD have no identified disclosures. 

CE Committee Member/Content Reviewers have nothing to disclose. 

Any/All relevant financial relationships have been mitigated. 

Content Disclosure: 

This presentation/content is HIPAA compliant. 

Commercial Support for this Session

None.